This webinar is intended to help cancer researchers and clinicians alike, better understand how genomic data can be used to gain insights into drug resistance, and will focus specifically on resistance and response in a specific subtype of breast cancer.
Next generation sequencing (NGS) has posed new challenges and opportunities in cancer treatment and drug development. These technologies have enabled clinicians and researchers the capability to identify variants in cancer pathways that may be predictive of response, and resistance to oncology therapeutics. However, NGS outputs are typically large & complex datasets that present challenges in interpretation.
During the webinar, the presenters will describe:
- Targeted sequencing solutions
- The analysis of NGS data generated using a targeted cancer sequencing panel from a multi-sample cohort of patients
- How this data has led to new insights into drug resistance and response in a specific breast cancer subtype
Particular emphasis will be placed on contextualization of variants with respect to biological pathways.
By attending this webinar, the audience can expect to gain insights into translational approaches that may be used to understand the biological implications of genomic variants and their interaction with drug response.
Sarah Bacus, PhD, Senior VP and Chief Scientific Officer, Translational R&D Oncology, Quintiles
Sarah Bacus is the Senior Vice President, Translational R&D – Oncology, Innovation and Chief Scientific Officer at Quintiles. Dr. Bacus has over 30 years of experience in basic and applied research in oncology drug development and diagnostics. Prior to her role at Quintiles, Dr. Bacus founded and sold four successful companies in the oncology field that were all focused on diagnostic and pre-clinical work for personalized medicine in oncology – CAS (Sold to Becton Dickinson); QDL (Sold to Ventana); TMD (Sold to Quintiles), and Oncotest (Sold to TEVA). Work performed by these companies revolutionized tissue imaging, facilitated accelerated approval of drugs such as lapatinib and established novel treatment strategies still currently in use today. Dr. Bacus has noteworthy accomplishments in preclinical drug development, applied and basic oncology research, personalized medicine and development of diagnostics and biomarkers which culminated in over 120 peer review papers, multiple worldwide patented biomarkers, and worldwide recognition as a leader in personalized medicine. Dr. Bacus holds professorships at Duke University and University of Illinois at Chicago. Dr. Bacus earned a BSc in Physics and Mathematics, M.Sc. in Biophysics and a PhD in Medical Physics at the Hebrew University in Israel.Message Presenter
Jeff Fitzgerald, Director, Personalized Medicine Integration, EA
Jeff brings to EA | Quintiles over a decade of successful sales and support experience in the genomics tools sector. In his current position he supports the integration of genomic technologies to address biomarker analysis in sponsors’ clinical trials.
Previously while at RainDance Technologies he cultivated new business opportunities in research and clinical markets through the use of its sequence enrichment solutions in conjunction with various next generation sequencing platforms. In previous sales and support roles at Affymetrix, he supported key genome and academic research centers in the use of expression, resequencing, and genotyping microarrays. Prior to his commercial experience, Jeff sought to identify molecular markers responsible for tumor progression while performing research in the Department of Pathology at Brigham and Women’s Hospital and Harvard Medical School.
Jeff holds a Bachelor of Science from the University of Vermont in Microbiology and Molecular Genetics.Message Presenter
EA | Quintile
EA | Quintiles provides cutting-edge genomic sequencing, gene expression, genotyping, and bioinformatics services to pharmaceutical companies, diagnostic test developers, government agencies, and academic labs. EA | Quintiles conducts projects under clinical-grade quality control and offers bioinformatics expertise and computational infrastructure to process genomic data with consistency and speed.